ARRY-502: Additional Phase II data
Additional data from a pre-defined subset of patients with an elevated median baseline value of fractional exhaled nitric oxide (FeNO) in a double-blind, U.S. Phase II trial showed that twice-daily 200 mg oral ARRY-502 significantly...